

Press Release

Astellas Announces Personnel Change

TOKYO, September 28, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following personnel change in its top management effective from November 1, 2023.

■ Appointment of new CFO

Mr. Atsushi Kitamura will join Astellas on November 1, 2023 and will be appointed as the new Chief Financial Officer (CFO) as of November 1, 2023. He has extensive knowledge and experience in the finance field, gained over many years in various industries including car electronics, food service, logistics, and consumer goods companies.

Top Management (Effective November 1, 2023)

Name	Title
Naoki Okamura	Representative Director,
	President and Chief Executive Officer (CEO)
Katsuyoshi Sugita	Representative Director, Executive Vice President
	Chief People Officer and Chief Ethics & Compliance Officer
	(CPO & CECO)
Yoshitsugu Shitaka	Chief Scientific Officer (CScO)
Tadaaki Taniguchi	Chief Medical Officer (CMO)
Hideki Shima	Chief Manufacturing Officer (CMfgO)
Claus Zieler	Chief Commercial Officer (CCO)
Adam Pearson	Chief Strategy Officer (CStO)
Atsushi Kitamura	Chief Financial Officer (CFO)
Catherine Levitt	General Counsel (GC)

^{*} As of November 1,2023, Naoki Okamura will no longer concurrently serve as CFO.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201

(Reference)

Curriculum Vitae of new Chief Financial Officer (CFO)

Name: Atsushi Kitamura

Career History:

April 2022 Pioneer Corporation, CFO / Board of Director (present post)

March 2020 Pioneer Corporation, CFO

March 2017 Skylark Holdings, CFO / Board of Director

July 2016 Skylark Holdings, CFO

September 2013 Skylark Holdings, Director Business Control

January 2010 TNT Express Worldwide (Japan) Inc.,

Finance Director/Board of Director

August 2009 TNT Express Worldwide (Japan) Inc., Finance Director

April 1995 Procter & Gamble Far East Inc.

(current Procter & Gamble Japan KK)